A Phase III Randomized Double-Blind Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients

The purpose of the study is to compare letermovir to valganciclovir in preventing CMV disease in patients who have received a kidney transplant and are considered to be at high-risk for CMV disease after their transplant. The main study intervention is taking letermovir (or placebo for letermovir) plus valanciclovir (or placebo for valganciclovir) for 28 weeks after kidney transplant, instead of receiving the standard of 6 months valganciclovir post-transplant.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  TBD
• Age: - 99 Years
• Gender: All